A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MMR / major molecular remission

[Related PubMed/MEDLINE]
Total Number of Papers: 17
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MMR  (>> Co-occurring Abbreviation)
Long Form:   major molecular remission
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. CML, IS, LC, MR, qRT, TM
2018 Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. CML, HR, PFS
2018 [Effect of Additional Chromosomal Abnormalities on the Outcome of CML-CP Patients Receiving TKI Therapy]. EFS, OS, PFS
2018 [Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib]. CCyR
2017 Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. TKI
2016 [Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations]. ABL-KDMs, allo-HSCT, CR, TKI
2015 A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system. IS
2015 A Pediatric Acute Promyelocytic Leukemia With a Rare Karyotype of ider(17)(q10)t(15;17) and Favorable Outcome: A Case Report. APL, ATRA, FISH, HCR
2015 [Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib]. CCyR, ELN, TKI
10  2014 [Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia]. CCgR, CML, CMR
11  2012 Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. CFUs, CML, IM
12  2011 Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. ACAs, CML, OS, PFS, Ph
13  2011 Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation. auto-HSCT, CHR, CML, IFN-alpha
14  2011 Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. CML, CP
15  2010 Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. CML, CP, DS, KD
16  2010 Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. CCyR, CML, CP, MRD, RT-qPCR
17  2009 Influence of late treatment on how chronic myeloid leukemia responds to imatinib. CML